630-580-1088 sales@ambeed.com
Structure Search

List Search MOL Search Structure Search

0
Chemistry
Asymmetric Synthesis >>Chiral Building BlocksChiral Catalysts, Chiral Ligands and Chiral ReagentsChiral Resolution ReagentsBoronic acids/esters >>Aliphatic BoronsAromatic BoronsOther BoronsOxaborolesCatalysis Chemistry >>Achiral Crown LigandsC-H ActivationCarbon-Donor LigandsChiral Carbon LigandsChiral Crown LigandsChiral Olefin LigandsCross-CouplingCross-Coupling Using Transition Metal CatalystsDACH or Trost LigandsChemical Biology >>Conjugation Chemistry
GlycoscienceLinkers and CrosslinkersNucleic Acid ChemistryPEGylationPeptide ChemistryPhotolabile Protecting GroupHeterocyclic Building Blocks >>AcridinesAliphatic HeterocyclesAromatic HeterocyclesAzetidinesBenzimidazolesBenzisoxazolesBenzodioxansBenzofuransBenzothiazolesInorganic reagents >>Inorganic reagentOrganic Building Blocks >>Acid AnhydridesAcyl Chlorides
AlcoholsAldehydesAliphatic Chain HydrocarbonsAliphatic Cyclic HydrocarbonsAlkenesAlkylsAlkynesOrganometallic Reagents >>Grignard ReagentsOrganoarsenicOrganobismuthOrganoboronOrganogermaniumOrganolithiumOrganomercuryOrganosiliconOrganotinSpecialty Synthesis >>Enzyme-Mediated SynthesisFluorous SynthesisIonic Liquids
Solid Supported SynthesisStains and Dyes >>Acid DyesAzoic DyesBasic DyesDirect DyesDisperse DyesDye IntermediatesMordant DyesOil DyesOther Stains and DyesSynthetic Reagents >>Acids and BasesC-C Bond FormationC-X Bond Formation (Halogen)C-X Bond Formation (Non-Halogen)Chelation and Complexation CompoundsCondensation AgentsCouplingDehydrating ReagentsFluorination Reagent
Pharmaceutical Intermediates
Analgesics >>BenzhydrocodoneBicifadineCapsaicinCelecoxibDebio-0827DexamethasoneElagolix SodiumEsketamine HydrochlorideIbuprofen sodiumAnesthetics >>CiprofolEsketamine HydrochlorideFospropofol Fospropofol DisodiumLevobupivacaine RemimazolamRemimazolam BesilateRemimazolam besylateRopivacaineAnti-Addiction Agents >>Kakonein
Lofexidine HydrochlorideVarenicline Anti-inflammatory Agents >>ApremilastAsunaprevirATB-346 RelatedBalsalazide BaricitinibBencycloquidium BromideBudesonideCefiderocol Sulfate TosylateCeftaroline Fosamil AcetateAntibacterials >>AFN-1252 RelatedAlatrofloxacin Bedaquiline FumarateBesifloxacin BrilacidinCaspofungin AcetateCefiderocol Sulfate TosylateCefilavancinCeftaroline Fosamil
Anticonvulsants >>BrivaracetamCannabidiolEscitalopram OxalateEslicarbazepine Acetate RelatedFosphenytoinGabapentin EnacarbilJNJ-10234094LacosamideLevetiracetam RelatedAntidementia Agents >>Azeliragon RelatedDavunetideDonepezil HydrochlorideDonepezil RelatedEnsaculinFlorbetaben Flortaucipir F 18Flutemetamol IdalopirdineAntidepressants >>4-Chlorokynurenine
AgomelatineAgomelatine RelatedAllopregnanolone RelatedAmibegronAmitifadineAripiprazole RelatedBasimglurantBefloxatoneAntiemetics >>AprepitantAprepitant RelatedDolasetron RelatedDolasetron Mesylate HydrateFosaprepitant DimeglumineFosaprepitant RelatedOlanzapinePalonosetron RelatedPalonosetron HydrochlorideAntifungals >>Anidulafungin RelatedCabotegravirMore >>
Inhibitors/Agonists
ADC >>ADC AntibodyADC LinkerADC Linker with PayloadADC ToxinAntibody-Drug Conjugates (ADCs)Drug-Linker Conjugates for ADCAngiogenesis >>ALKBcr-AblBTKEGFRFAKFGFRFLT3HER2HIFAnti-infection >>3CLproAntibacterialAntibioticAntifungal
AntiparasiticAntiprotozoalAntiviralArenavirusBVDVApoptosis >>Apoptosis InducerBcl-2Bcl-6BRKc-Mycc-RETC/EBPCARDCaspaseAutophagy >>Atg4ATG4BATTECsAUTACsAutophagyBeclin1
FKBPLC3LRRK2Biochemical Reagent >>Cell Cycle >>AntifolateAPCAurora KinaseBUBCasein KinaseCdc25CDKChkCRISPR/Cas9Cytoskeleton >>ActinArp2/3 ComplexCYTHCytoplasmic dyneinDynaminFAKMore >>
Material Science
Aggregation-Induced Emission >>Other AIE BlocksTetraphenylethylene SeriesCOFs Linkers >>Aldehyde COFs LinkersAlkynyl COFs LinkersAmine COFs LinkersBoric COFs LinkersCyano COFs LinkersMultifunctional COFs linkersOther COFs linkersTriphene seriesElectronic Materials >>Battery MaterialsDye-Sensitized Solar Cell (DSSC) MaterialsElectronic MaterialLiquid Crystal (LC) MaterialsMolecular ConductorsOrganic Light-Emitting Diode (OLED) MaterialsOrganic Solar Cell (OPV) MaterialsOrganic Transistor (OFET) MaterialsPerovskite Solar Cell (PSC) MaterialsMagnetic Materials >>Magnetic Ionic LiquidsMagnetic MaterialMagnetic Metal Complexes
Organic Radicals Material Chemical Compounds >>Ligands for Functional Metal ComplexesLiquid Crystal (LC) Building BlocksPhthalocyanine Building BlocksPolymer and Macromolecule Semiconductor Building BlocksSmall Molecule Semiconductor Building BlocksSolubility Enhancing Reagents Supramolecular Host Materials MOF Ligands >>Carboxylic Acid MOF LigandsCarboxylic Acid Nitrogen-Containing Mixed MOF LigandsNitrogen-Containing MOF LigandsOther MOF ligandsNanomaterials >>Carbon NanomaterialsCeramic MembranesDendrimersGold NanoparticlesIron Oxide NanoparticlesMaterials by ApplicationMesoporous MaterialsMetals and Metal AlloysNano Minerals: NanoclaysOLED Materials >>Dopant
HostHTMOLED IntermediatesOther OLED related materialsOptical Materials >>Coumarin DyesCyanine and Squarylium DyesDCM DyesDipyrromethene DyesFluorescence MaterialsFluorescent ProbesHeat and Pressure Sensitive DyesNear-Infrared (NIR) DyesOrganic Non-Linear Optical (NLO) MaterialsOrganic Pigments >>Organic PigmentOther Materials >>Mateial OtherPolymer Science >>MonomersPolymer AdditivesPolymerization ReagentsPolymersResins
Contact Us
Home Cart 0 Sign in  
Chemistry
Organometallic Reagents
Organoboron
tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate
Chemistry
Organometallic Reagents
Heterocyclic Building Blocks Organic Building Blocks Boronic acids/esters
Organoboron
Piperazines Aryls Amides Esters Carbamates Aromatic Borons Aliphatic Heterocycles

[ CAS No. 540752-87-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 540752-87-2
Chemical Structure| 540752-87-2
Structure of 540752-87-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 540752-87-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 540752-87-2 ]

SDS Specification
Alternatived Products of [ 540752-87-2 ]

Product Details of [ 540752-87-2 ]

CAS No. :540752-87-2 MDL No. :MFCD07781212
Formula : C21H33BN2O4 Boiling Point : -
Linear Structure Formula :- InChI Key :RJUYJGNYCCEDAH-UHFFFAOYSA-N
M.W : 388.31 Pubchem ID :16414220
Synonyms :

Calculated chemistry of [ 540752-87-2 ]

Physicochemical Properties

Num. heavy atoms : 28
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.67
Num. rotatable bonds : 5
Num. H-bond acceptors : 4.0
Num. H-bond donors : 0.0
Molar Refractivity : 120.12
TPSA : 51.24 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.05 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 3.69
Log Po/w (WLOGP) : 2.28
Log Po/w (MLOGP) : 1.97
Log Po/w (SILICOS-IT) : 1.72
Consensus Log Po/w : 1.93

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.4
Solubility : 0.0154 mg/ml ; 0.0000397 mol/l
Class : Moderately soluble
Log S (Ali) : -4.46
Solubility : 0.0136 mg/ml ; 0.000035 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.61
Solubility : 0.00955 mg/ml ; 0.0000246 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.75

Safety of [ 540752-87-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 540752-87-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 540752-87-2 ]

[ 540752-87-2 ] Synthesis Path-Downstream   1~68

  • 1
  • [ 540752-87-2 ]
  • [ 56-05-3 ]
  • [ 540752-88-3 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 2
  • [ 540752-86-1 ]
  • [ 73183-34-3 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 3
  • [ 198627-86-0 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 4
  • [ 862261-23-2 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 5
  • [ 540752-87-2 ]
  • [ 540752-08-7 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 6
  • [ 540752-87-2 ]
  • 2-furan-2-yl-7-{3-[4-(propane-2-sulfonyl)-piperazin-1-yl]-phenyl}-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-5-ylamine [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 7
  • [ 540752-87-2 ]
  • 4-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-7-yl)-phenyl]-piperazine-1-carboxylic acid isopropyl ester [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 8
  • [ 540752-87-2 ]
  • [ 540751-83-5 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 9
  • [ 540752-87-2 ]
  • 2-furan-2-yl-7-{3-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-phenyl}-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-5-ylamine [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 10
  • [ 540752-87-2 ]
  • 1-{4-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-7-yl)-phenyl]-piperazin-1-yl}-2-(2-methyl-morpholin-4-yl)-ethanone [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 11
  • [ 540752-87-2 ]
  • 1-{4-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-7-yl)-phenyl]-piperazin-1-yl}-2-morpholin-4-yl-ethanone [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 12
  • [ 57260-71-6 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
[2]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
[3]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 13
  • [ 571202-87-4 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 3675 - 3678
  • 14
  • [ 540752-87-2 ]
  • [ 705263-10-1 ]
  • C21H25N5O2 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4388 - 4392
YieldReaction ConditionsOperation in experiment
[10] Tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used as a reagent and after coupling, the Boc group was removed with trifluoroacetic acid in DCM. The resultant product gave the following characterising data: Mass Spectrum: M+H+ 372.11; RT 2.41 min; NMR Spectrum: (DMSOd6) 8.56 (1H, d), 8.47 (1H, d), 7.79-7.88 (2H, m), 7.76 (2H, s), 7.41-7.50 (2H, m), 7.31 (1H, t), 7.18 (1H, s), 7.07 (1H, d), 6.92 (1H, dd), 3.15 (4H, t), 2.87 (4H, t). The tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate used as a reagent was prepared as follows:
With 1,1'-bis-(diphenylphosphino)ferrocene; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate; In 1,4-dioxane; at 80℃; for 4h; General procedure: An oven dried resealable Schlenk tube was charged with tert-butyl [2-(3-bromophenyl)ethyl]carbamate (preparation 3a, 0.29 g, 0.96 mmol), bis(pinacolato)diboron (0.27 g, 1.05 mmol), potassium acetate (0.28 g, 2.88 mmol) and dioxane (4 mL). The Schlenk tube was subjected to three cycles of evacuation-backfilling with argon, and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (0.02 g, 0.03 mmol) and 1,1'-bis(diphenylphosphino)ferrocene (0.02 g, 0.03 mmol) were added. After three further cycles of evacuation-backfilling with argon, the Schlenk tube was capped and placed in an oil bath at 80 C. After 4h, the mixture was cooled and ethyl acetate and satured aqueous trimethylammonium chloride solution was added. The organic layer was washed with satured aqueous trimethylammonium chloride solution, dried (MgSO4) and evaporated to give the desired compound in quantitative yield. The crude material was used without further purification.LRMS (m/z): 264 (M-1)-.
General procedure: Step-ii: 1-(2-fluorobenzyl)-4-( 4,4,5 ,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-pyrazole1-(2-fluorobenzyl)-4-iodo-1H-pyrazole (2.25 g, 7.4 mmol) and bispinocalatodiboron (2.07 g,8.2 mmol) were added to a solution of DMSO (20 ml) previously purged with argon (10min). The reaction mixture was purged with argon for a further 15mins, followed by the10 addition of potassium acetate (2.19 g, 22.3 mmol) andbis(triphenylphosphine)palladium(II)dichloride (261 mg, 0.3725 mmol). The resultingmixture was heated to reflux at 80 oc overnight. The reaction was monitored by TLC (40%ethyl acetate in hexane). The reaction mixture was cooled and diluted with ethyl acetate (100ml) and filtered over celite bed and the filtrate was washed with cold water (2x100 ml). The15 organic layer was dried over NazS04, and concentrated under reduced pressure to afford 2.3 gof the crude product which was taken as such for next reaction.
  • 16
  • [ 123-91-1 ]
  • Dichlorobis(triphenylphosphine)palladium (TI) [ No CAS ]
  • [ 73183-34-3 ]
  • [ 327030-39-7 ]
  • [ 540752-87-2 ]
YieldReaction ConditionsOperation in experiment
With nitrogen; potassium acetate; In phosphorus pentaoxide; 2-Methylpentane; ethyl acetate; Dichlorobis(triphenylphosphine)palladium (TI) (0.172 g), tert-butyl 4-(3-bromophenyl)piperazine-1-carboxylate (3.59 g), bis(pinacolato)diboron (3.21 g) and potassium acetate (2.06 g) were combined in a flask which was then dried in a dessicator containing phosphorus pentoxide. The flask was then flushed with nitrogen and 1,4-dioxane (100 ml) was added. The resulting suspension was stirred at 80 C. for 20 hours. The mixture was allowed to cool and then the solvent was evaporated under reduced pressure. The residue was redissolved in ethyl acetate (100 ml) and washed with water (100 ml), then dried over magnesium sulfate, filtered through a silica pad and evaporated. The resultant product was purified by flash silica chromatography (elution solvent 25% ethyl acetate in isohexane). There was thus obtained tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (3.34 g); Mass Spectrum: M+H=389; RT 3.23 min; NMR Spectrum: (DMSOd6) 7.32 (3H, m), 7.02 (1H, ddd), 3.57 (4H, t), 3.15 (4H, t), 1.48 (9H, s), 1.33 (12H, s).
Reference： [1]Patent: US2009/118305,2009,A1
  • 17
  • [ 540752-87-2 ]
  • [ 1138473-16-1 ]
  • [ 1138473-18-3 ]
YieldReaction ConditionsOperation in experiment
30% [0198] To a microwave reaction tube was charged with 11 (70 mg, 0.15 mmol), 4-[3-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester (70 mg, 0.18 mmol) and Pd(PPh3)4 (20 mg, 0.017 mmol). DMF (3 mL) was added to the above mixture followed by aqueous sodium carbonate (2 M; 0.3 mL, 0.6 mmol). The reaction tube was sealed and the suspension irradiated with microwave at 160 0C for 20 min. After cooling to room temperature, the mixture was filtered and the filtered solid washed with DCM. The filtrate was concentrated and the residue suspended in a mixture of DCM/TFA (5/3, 8 mL). The mixture was stirred at 60 0C for 1 h and then concentrated. The crude product was purified by HPLC, the corrected fractions combined and poured into saturated NaHCO3 solution (30 mL). The combined aqueous layers were extracted with EtOAc (2 x 30 mL) and the combined organic layers washed with brine, dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated and the residue re-dissolved in minimum amount of EtOAc and hexanes added until solid precipitated. After filtration, the title compound was obtained as a yellow solid (25 mg, 30% in 2 steps). 1H NMR (500 MHz, DMSO-d6): delta 1.60-1.70 (m, 4H), 2.42 (s, 3H), 2.48-2.55 (m, 4H), 2.78 (t, J = 5.9 Hz, 2H), 2.90 (t, J = 5.0 Hz, 4H), 3.16 (t, J = 5.0 Hz, 4H), 4.03 (t, J = 6.0 Hz, 2H), 6.90 (d, J = 9.1 Hz, 2H), 6.96 (dd, J = 8.3, 2.1 Hz, IH), 7.17 (d, J = 8.0 Hz, IH), 7.24 (s, IH), 7.30 (t, J = 8.0 Hz, IH), 7.62 (d, J = 4.0 Hz, IH), 7.71 (d, J = 9.0 Hz, 2H), 7.74 (d, J = 4.0 Hz, IH), 8.34 (s, IH), 9.31 (s, IH)MS (ES+): m/z 541 (M+H)+
Reference： [1]Patent: WO2009/46416,2009,A1 .Location in patent: Page/Page column 61-62
  • 18
  • [ 540752-87-2 ]
  • [ 1247001-86-0 ]
  • [ 1247001-89-3 ]
  • C33H35N5O4 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium carbonate;bis-triphenylphosphine-palladium(II) chloride; In 1,2-dimethoxyethane; ethanol; water; at 125℃; for 2h;Autoclave; Microwave irradiation; Example A47. (l Rit..2S*)-5'-methoxy-2-(3-(3-(piperazin-l-vnphenyl)-l H-indazol-6- yl)spirorcvclopropane-l ,3'-indolinl-2'-one 2,2,2-trifluoroacetateS*, racemate A mixture of (R, 2S)- and (S, 2Lambda)-2-(3-Iodo-lH-indazol-6-yl)-5'- methoxyspiro[cyclopropane-l ,3'-indolin]-2'-one (50 mg, 0.12 mmol), tert-butyl 4-(3- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)piperazine-l-carboxylate (50 mg, 0.13 mmol), PdCl2(PPh3)2 (8 mg, 0.01 mmol) and 2M Na2CO3 (60 uL, 0.12 mmol) in DME/Eta2O/EtOEta (2.1 mL/0.6 mL/0.3 mL) was sealed and heated with stirring under microwave irradiation at 125 0C for 120 min. The crude reaction mixture was concentrated under reduced pressure to dryness, and purified by flash chromatography using hexanes/EtOAc as eluent (60:40 to 20:80) to give a pale yellow solid.The intermediate was dissolved in CH2Cl2 (3 mL) and TFA (30 uL) was added. The resulting mixture was stirred at rt for 4 h. The crude reaction mixture was concentrated under reduced pressure to dryness, and purified by preparative HPLC to give the title compound as a yellow powder and as the TFA salt (25 mg, 37%). 1H NMR (400 MHz, DMSOd6) delta 13.21 (s, I H), 10.45 (s, I H), 8.68 (br s, 1), 7.92 (d, J = 8.4 Jz. I H), 7.53-7.45 (m, 3H), 7.39 (t, J = 8.0 Hz, I H), 7.04-7.02 (m, 2H), 6.74 (d, J = 8.4 Hz, I H), 6.57 (dd, J = 8.4, 2.4 Hz, I H), 5.71 (d, J = 2.5 Hz, IH), 3.43-3.34 (m, I H), 3.29 (s, 3H), 3.29-3.24 (m, 3H), 3.23-3.16 (m 2H), 2.36-2.32 (m, I H), 2.02-1.98 (m, I H); MS ESI 466.3 [M + H]+, calcd for [C28H27N5O2 + H]+ 466.22.
Reference： [1]Patent: WO2010/115279,2010,A1 .Location in patent: Page/Page column 168-169
  • 19
  • [ 540752-87-2 ]
  • [ 1201786-91-5 ]
  • [ 1201789-91-4 ]
YieldReaction ConditionsOperation in experiment
80% With caesium carbonate;(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; In 1,2-dimethoxyethane; water; at 110℃; for 7h;Inert atmosphere; Sealed tube; Compound 116 is prepared in the same manner as compound 114 starting with 3-bromo-6-(pyrid-3-yl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine 6 (600 mg, 1.85 mmol) and <strong>[540752-87-2]tert-butyl 4-[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate</strong> (930 mg, 2.39 mmol) to give 116 in the form of a brown solid (824 mg, 80%).MS: m/z=507 (ES+).1H NMR (300 MHz, DMSO-d6) delta ppm 12.37 (s, 1H), 9.38 (s, 1H), 9.05 (s, 1H), 9.04 (s, 1H), 8.98 (s, 1H), 8.95 (s, 1H), 8.60 (d, 1H), 8.52 (d, 1H), 7.55 (dd, 1H), 7.40 (t, 1H), 7.37 (s, 1H), 7.26 (d, 1H), 7.02 (d, 1H), 3.51 (t, 4H), 3.25 (t, 4H), 1.44 (s, 9H).
Reference： [1]Patent: US2011/178053,2011,A1 .Location in patent: Page/Page column 88
  • 20
  • [ 540752-87-2 ]
  • [ 1370453-96-5 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
  • 21
  • [ 540752-87-2 ]
  • [ 1370454-38-8 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
  • 22
  • [ 540752-87-2 ]
  • [ 1370454-02-6 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
  • 23
  • [ 540752-87-2 ]
  • [ 1370454-40-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
  • 24
  • [ 540752-87-2 ]
  • [ 19798-81-3 ]
  • [ 1370453-99-8 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
  • 25
  • [ 591-18-4 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
  • 26
  • [ 73183-34-3 ]
  • [ 327030-39-7 ]
  • [ 540752-87-2 ]
YieldReaction ConditionsOperation in experiment
83.2% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate; In 1,4-dioxane; at 110℃; for 5h; To a solution of 42c (0.94 g, 2.75 mmol) in dioxane (30 mL) was added 4,4,4?,4?,5,5,5?,5?-octamethyl-2,2?-bi(1,3,2-dioxaborolane) (1.40 g, 5.51 mmol), KOAc (811 mg, 8.26 mmol), Pd(dppf)Cl2 (0.27 mmol), and dioxane (15 mL). The reaction system was purged and stirred at 110 C. for 5 h. The reaction mixture was cooled to 25 C. and poured into water (15 mL), extracted with EtOAc (20 mL×3). The organic layer was dried over Na2SO4, concentrated, and by purified by column (PE:EtOAc=15:1-10:1) to give tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate 42d (0.89 g, yield: 83.2%). LCMS: (5-95, AB, 1.5 min), 1.015 min, MS=388.8 [M+1].
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 5419 - 5423
[2]Patent: US2016/272588,2016,A1 .Location in patent: Paragraph 0279; 0282
[3]Patent: WO2018/183633,2018,A1 .Location in patent: Paragraph 0042
[4]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 27
  • [ 540752-87-2 ]
  • [ 1312595-04-2 ]
  • [ 1312595-13-3 ]
YieldReaction ConditionsOperation in experiment
A mixture of 1 ,1 -dimethylethyl 4-(3-bromo-4-[(3-chlorophenyl)sulfonyl]amino}-6- methylthieno[2,3-6]pyridin-2-yl)-1 /-/-pyrazole-1 -carboxylate (Description 75) (100 mg, 0.171 mmol), 3-(4-ferf-butoxycarbonylpiperazinyl)phenylboronic acid, pinacol ester (133 mg, 0.343 mmol), potassium carbonate (71.0 mg, 0.514 mmol),tetrakis(triphenylphosphine)palladium(0) (19.79 mg, 0.017 mmol) andbis(triphenylphosphine)palladium(ll) chloride (12.02 mg, 0.017 mmol) were weighed into a microwave vial. 1 ,4-Dioxane (2 mL), DMF (1 mL) and water (0.5 mL) were added and the mixture heated in a microwave at 120C for 15 min. At this point, all three mixtures were combined and concentrated. The residue was then passed through an SCX cartridge, eluting with MeOH (150 mL) and then 2M NH3 in MeOH (200 mL). The basic methanolic solution was concentrated and purified by normal phase chromatography, eluting with 0-100% ethyl acetate in DCM to give a residue (168 mg), which was subsequently taken-up in DCM (5 mL) and TFA (1 mL) added. The reaction mixture was stirred at RT for ca. 1 h and was then passed through an SCX cartridge, eluting with MeOH (100 mL) and then with 2M NH3 in MeOH (150 mL). The basic methanolic solution was concentrated and purified by normal phase chromatography, eluting with 0-20% 2M NH3 in MeOH in DCM to give a solid (ca. 125 mg). The solid was suspended in DCM (5 mL) and HCI (2M in diethyl ether) (0.128 mL, 0.257 mmol) was added. The mixture was stirred at RT for 30 min and solvent was then removed. The solid was triturated with DCM (5 mL x 3) and then dried in vacuum oven, to give the title compound (102 mg) as hydrochloride salt. LCMS (A) m/z: 565 [M+1 ]+, Rt 0.95 min (acidic).
Reference： [1]Patent: WO2011/75559,2011,A1 .Location in patent: Page/Page column 119; 120
  • 28
  • [ 540752-87-2 ]
  • [ 1312594-13-0 ]
  • [ 1312594-16-3 ]
YieldReaction ConditionsOperation in experiment
With potassium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,4-dioxane; water; at 120℃; for 0.5h;microwave irradiation; Inert atmosphere; Under nitrogen, 3-bromo-2,6-dimethylthieno[2,3-6]pyridin-4-amine (130 mg, 0.506 mmol) (Description 8) was dissolved in 1 ,4-dioxane (3 mL) and water (1 mL) and 1 ,1 - dimethylethyl 4-[3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl]-1- piperazinecarboxylate (294 mg, 0.758 mmol), tetrakis(triphenylphosphine)palladium(0) (58.4 mg, 0.051 mmol) and potassium carbonate (210 mg, 1.517 mmol) were added. The mixture was then heated in a microwave at 120C for 30 min. Ethyl acetate (10 mL) was added and the mixture washed with water (2 x 5 mL). The organic layer was dried over MgS04, filtered and solvent removed in vacuo. Purification by chromatography on silica gel, eluting with a gradient of 0-70% ethyl acetate in cyclohexane, afforded the title compound (197 mg). LCMS (A) m/z: 439 [M+1]+, Rt 0.99 min (acidic).
Reference： [1]Patent: WO2011/75559,2011,A1 .Location in patent: Page/Page column 30
  • 29
  • [ 540752-87-2 ]
  • ethyl (2E)-3-(3-[(3-bromonaphthalen-1-yl)carbonyl]amino}phenyl)prop-2-enoate [ No CAS ]
  • tert-butyl 4-{3-[4-({3-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]phenyl}carbamoyl)naphthalen-2-yl]phenyl}piperazine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
53% With dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane; palladium diacetate; caesium carbonate; In ethanol; toluene; at 20 - 110℃; for 1.16667h;Microwave irradiation; General procedure: Method J: To the mixture of 5 mol% of S-Phos, 5 mol% of Pd(OAc)2, compound 15 (1 equivalent), 2-fluoro- phenylboronic acid (1.5 equivalents) and Cs2CO3 (3 equivalents) a mixture of toluene/ethanol (1:1) was added and stirred at room temperature for 10 mm, and then irradiated at 110 C for 1 h, using the microwave reactor. After irradiation, the sample was cooled and the solvent was evaporated to dryness.The resulting residue was extracted with EtOAc; the organic layer was washed with brine and dried over Na2SO4 and the solvent evaporated to dryness to afford crude 16a. Purified material was obtained by silica gel column chromatography using EtOAc/Petrol ether as the eluent. Compound 24b (302 mg, 53%) was obtained by coupling 23 (400 mg, 0.92 mmol) with {3-[4-(tert- butoxycarbonyl)piperazin-1-yl]phenyl} boronic ester (439.3 mg, 1.13 mmol) using S-Phos (15.0 mg,0.036 mmol), Pd(OAc)2 (4.1 mg, 0.018 mmol) and Cs2CO3 (601 mg, 1.84 mmol) using the general procedure described above for 16a-g. This material was used directly for the next step. LC-ESMS m/z 606.08[M+1] HPLC; 95.7%; Yield= 53%.
Reference： [1]Patent: WO2013/164326,2013,A1 .Location in patent: Page/Page column 20; 21; 22; 29; 30
  • 30
  • [ 540752-87-2 ]
  • [ 1450642-83-7 ]
  • [ 1534378-52-3 ]
YieldReaction ConditionsOperation in experiment
89.7% Using similar reaction conditions as described in step-ii of example-1, 5-bromo-3-(l-(2,5-difluorobenzyl)-IH-pyrazol-4-yl)-l-tosyl-1H-pyrrolo[2,3-b ]pyridine (step-i of example-4)(380mg, 0.552mmol) was coupled with tert-butyl 4-(3-( 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl) piperazine-1-carboxylate (intermediate 37) ( 428mg, 1.104mmol)in sodium carbonate (176mg, 1.657mmol), Pd(PPh3)zCh (38.7mg, 0.0552mmol),25 toluene/ethanol/water (30/15/6 ml). This afforded 454mg (89.7% yield) after purification bycolumn (Silica gel60/120) using 35%ethyl acetate in hexane as eluent.MS: m/z = 725.6 (M+2)
Reference： [1]Patent: WO2014/6554,2014,A1 .Location in patent: Page/Page column 79
  • 31
  • [ 540752-87-2 ]
  • [ 1450642-74-6 ]
  • [ 1534378-53-4 ]
YieldReaction ConditionsOperation in experiment
48.6% Using similar reaction conditions as described in step-ii of example-1, 5-bromo-3-(1-(3-5 fluorobenzyl)-1H-pyrazol-4-yl)-l-tosyl-1H-pyrrolo[2,3-b ]pyridine (compound of step-i ofexample-9) (225 mg, 0.428mmol) was coupled with tert-butyl 4-(3-(4,4,5,5-tetramethyl-1 ,3 ,2-dioxaborolan-2-yl) phenyl) piperazine-1-carboxylate (intermediate 3 7) (332mg,0.857mmol) in sodium carbonate (182mg, 1.714mmol), Pd(PPh3)zCh (34mg, 0.0285mmol),toluene/ethanol/water (22/11/5.5 ml). This afforded 147mg (48.6% yield) after purification10 by column (Silica gel 601120) using 35%ethyl acetate in hexane as eluent.MS: m/z = 706.8 (M+ 1)
Reference： [1]Patent: WO2014/6554,2014,A1 .Location in patent: Page/Page column 81
  • 32
  • [ 540752-87-2 ]
  • [ 1186608-83-2 ]
  • [ 1616388-21-6 ]
YieldReaction ConditionsOperation in experiment
23% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate; In water; acetonitrile; at 120 - 150℃; for 3.16667h;Microwave irradiation; To 3-bromo-5-nitro- lH-pyrazolo[3,4-b]pyridine 111 (0.1 g, 0.41 mmol) in acetonitrile (3 ml) were added tert-butyl 4-[3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl]piperazine- 1 -carboxylate 112 (0.2 g, 0.52 mmol), [1,1 '- bis(diphenylphosphino)ferrocene]dichloropalladium(ii) (12 mg, 0.016 mmol), and aqueous potassium carbonate (1 ml, 1 M). The reaction mixture was irradiated in microwave at 120 C for 20 minutes and at 150C for 170 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed by brine and dried under sodium sulfate. After removal of drying agent and solvent, the residue was purified by silica gel column chromatography to provide compound 113 as a brownish solid (58 mg, 23%). MS(ESI) [M-H-]- = 423.20.
Reference： [1]Patent: WO2014/100620,2014,A2 .Location in patent: Paragraph 0357
  • 33
  • [ 540752-87-2 ]
  • [ 1616385-69-3 ]
Reference： [1]Patent: WO2014/100620,2014,A2
  • 34
  • [ 540752-87-2 ]
  • [ 1616388-22-7 ]
Reference： [1]Patent: WO2014/100620,2014,A2
  • 35
  • [ 540752-87-2 ]
  • [ 1616387-14-4 ]
Reference： [1]Patent: WO2014/100620,2014,A2
  • 36
  • [ 540752-87-2 ]
  • 2-amino-5-bromo-3-(3,4,5-trimethoxyphenyl)pyridine [ No CAS ]
  • C29H36N4O5 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,2-dimethoxyethane; water; at 90℃; for 8h; General procedure: To a solution of 5 ( 1.0 equiv), [(N-Boc)piperazin- 1 -y I jpheiw boronic acid pinacoi ester ( 1.1 equiv) and Pd(PPhs j (0.12 equiv) in DME, (iM) aqueous Na2C( (2.0 equiv) was added. The reaction mixture was stirred under argon atmosphere at 90 C for 8 h. The reaction mixture was filtered and concentrated. The residue was purified by flash column chromatography, eiuting with a mixture cyclohexane EtOAc to give 6
Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 7900 - 7915
[2]Patent: WO2016/54406,2016,A1 .Location in patent: Page/Page column 53; 54
  • 37
  • [ 540752-87-2 ]
  • C14H10BrN3 [ No CAS ]
  • C29H31N5O2 [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 7900 - 7915
  • 38
  • [ 540752-87-2 ]
  • C13H18Cl2N4O [ No CAS ]
  • C28H39ClN6O3 [ No CAS ]
  • C28H39ClN6O3 [ No CAS ]
Reference： [1]ACS Medicinal Chemistry Letters,2014,vol. 5,p. 1235 - 1239
  • 39
  • [ 540752-87-2 ]
  • C13H18Cl2N4O [ No CAS ]
  • C24H34N6O [ No CAS ]
Reference： [1]ACS Medicinal Chemistry Letters,2014,vol. 5,p. 1235 - 1239
  • 40
  • [ 540752-87-2 ]
  • 4-(4-chloropyridin-3-yl)-2,6-difluorophenol [ No CAS ]
  • C26H27F2N3O3 [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 6766 - 6783
  • 41
  • [ 31197-30-5 ]
  • [ 540752-87-2 ]
Reference： [1]Patent: US2016/272588,2016,A1
  • 42
  • [ 540752-87-2 ]
  • 3-bromo-4-ethyl-5-(3-(piperazin-1-yl)phenyl)pyridin-2-amine [ No CAS ]
Reference： [1]Patent: US2016/272588,2016,A1
  • 43
  • [ 540752-87-2 ]
  • 4-[2-amino-4-ethyl-5-(3-piperazin-1-ylphenyl)-3-pyridyl]phenol [ No CAS ]
Reference： [1]Patent: US2016/272588,2016,A1
  • 44
  • [ 540752-87-2 ]
  • tert-butyl (3,5-dibromo-4-ethylpyridin-2-yl)carbamate [ No CAS ]
  • tert-butyl 4-(3-(5-bromo-6-((tert-butoxycarbonyl)amino)-4-ethylpyridin-3-yl)phenyl)piperazine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
43.2% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate; In 1,4-dioxane; water; at 120℃; for 0.833333h;Inert atmosphere; Microwave irradiation; To a solution of 42d (400 mg, 1.03 mmol) in dioxane-H2O (5 mL) was added tert-butyl (3,5-dibromo-4-ethylpyridin-2-yl)carbamate 42e (391 mg, 1.0 mmol), K2CO3 (427 mg, 3.09 mmol) and Pd(dppf)Cl2 (45 mg). The reaction mixture was purged with N2 and heated with microwave irradiation at 120 C. for 50 min. The reaction mixture was cooled to 25 C. then poured to water (15 mL). It was extracted with EtOAc (3×20 mL) and the organic layer was dried over Na2SO4, concentrated it and purified by column (PE:EtOAc=20:1-5:1) to give tert-butyl 4-(3-(5-bromo-6-((tert-butoxycarbonyl)amino)-4-ethylpyridin-3-yl)phenyl)piperazine-1-carboxylate 42f (250 mg, yield: 43.2%).
Reference： [1]Patent: US2016/272588,2016,A1 .Location in patent: Paragraph 0279; 0283
  • 45
  • [ 24424-99-5 ]
  • [ 540752-87-2 ]
Reference： [1]Patent: US2016/272588,2016,A1
  • 46
  • [ 540752-87-2 ]
  • 7-bromo-5-(1-cyclopropyl-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine [ No CAS ]
  • C27H32N8O2 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 47
  • [ 540752-87-2 ]
  • 7-bromo-5-(1-isopropyl-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine [ No CAS ]
  • C27H34N8O2 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 48
  • [ 540752-87-2 ]
  • C12H11BrN6O [ No CAS ]
  • C27H32N8O3 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 49
  • [ 540752-87-2 ]
  • 7-bromo-5-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine [ No CAS ]
  • C26H29F3N8O2 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 50
  • [ 540752-87-2 ]
  • 7-bromo-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine [ No CAS ]
  • C29H36N8O3 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 51
  • [ 108-36-1 ]
  • [ 540752-87-2 ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 855 - 861
  • 52
  • [ 24424-99-5 ]
  • [ 31197-30-5 ]
  • [ 540752-87-2 ]
Reference： [1]Patent: WO2018/183633,2018,A1
  • 53
  • [ 540752-87-2 ]
  • [ 3934-20-1 ]
  • tert-butyl 4-(3-(2-chloropyrimidin-4-yl)phenyl)piperazine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In tetrahydrofuran; water; at 60℃; for 24h;Inert atmosphere; The mixture of 2,4-dichloropyrimidine (500 mg, 3.36 mmol), <strong>[540752-87-2]tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate</strong> (1.24 g), tetrakis(triphenylphosphine)palladium(0) (739 mg), sodium carbonate (508 mg), THF (20 mL) and water (2.00 mL) was stirred at 60 C. under nitrogen atmosphere for 24 hr. The mixture was quenched with water at room temperature and extracted with ethyl acetate. The organic layer was separated, washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate/hexane) to give the title compound. MS m/z 375.1 [M+1]+.
With tetrakis(triphenylphosphine)palladium (0); A) tert-butyl 4-(3-(2-chloropyrimidin-4-yl)phenyl)piperazine-1-carboxylate A mixture of 2,4-dichloropyrimidine (500 mg), <strong>[540752-87-2]tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate</strong> (1.24 g), tetrakis(triphenylphosphine)palladium(0) (739 mg), sodium carbonate (508 mg), THF (20 mL) and water (2.0 mL) was stirred at 60 C. under nitrogen atmosphere for 24 hr. The mixture was quenched with water at room temperature and extracted with ethyl acetate. The organic layer was separated, washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/hexane) to give the title compound. MS m/z 375.1 [M+1]+.
Reference： [1]Patent: US2018/280389,2018,A1 .Location in patent: Paragraph 3872; 3873
[2]Patent: US2020/95240,2020,A1
  • 54
  • [ 540752-87-2 ]
  • 5,5-difluoro-7,9-dimethyl-3-(3-oxo-3-((3-((4-(3-(piperazin-1-yl)phenyl)pyrimidin-2-yl)amino)phenyl)amino)propyl)-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide [ No CAS ]
Reference： [1]Patent: US2018/280389,2018,A1
  • 55
  • [ 540752-87-2 ]
  • tert-butyl 4-(3-(2-((3-nitrophenyl)amino)pyrimidin-4-yl)phenyl)piperazine-1-carboxylate [ No CAS ]
Reference： [1]Patent: US2018/280389,2018,A1
[2]Patent: US2020/95240,2020,A1
  • 56
  • [ 540752-87-2 ]
  • tert-butyl 4-(3-(2-((3-aminophenyl)amino)pyrimidin-4-yl)phenyl)piperazine-1-carboxylate [ No CAS ]
Reference： [1]Patent: US2018/280389,2018,A1
[2]Patent: US2020/95240,2020,A1
  • 57
  • [ 540752-87-2 ]
  • 3-(3-((3-((4-(3-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenyl)pyrimidin-2-yl)amino)phenyl)amino)-3-oxopropyl)-5,5-difluoro-7,9-dimethyl-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide [ No CAS ]
Reference： [1]Patent: US2018/280389,2018,A1
  • 58
  • [ 540752-87-2 ]
  • [ 591-50-4 ]
  • methyl 5-(4-(pivaloyloxy)phenyl)pent-4-ynoate [ No CAS ]
  • (Z)-tert-butyl 4-(3-(5-methoxy-5-oxo-2-phenyl-1-(4-(pivaloyloxy)phenyl)pent-1-en-1-yl)phenyl)piperazine-1-carboxylate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 59
  • [ 540752-87-2 ]
  • (Z)-methyl 4-phenyl-5-(3-(piperazin-1-yl)phenyl)-5-(4-(pivaloyloxy)phenyl)pent-4-enoate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 60
  • [ 540752-87-2 ]
  • (Z)-methyl 4-phenyl-5-(3-(piperazin-1-yl)phenyl)-5-(3-(pivaloyloxy)phenyl)pent-4-enoate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 61
  • [ 540752-87-2 ]
  • (Z)-methyl 5-(3-(4-isopropylpiperazin-1-yl)phenyl)-4-phenyl-5-(4-(pivaloyloxy)phenyl)pent-4-enoate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 62
  • [ 540752-87-2 ]
  • (E)-methyl 5-(3-(4-isopropylpiperazin-1-yl)phenyl)-4-phenyl-5-(3-(pivaloyloxy)phenyl)pent-4-enoate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 63
  • [ 540752-87-2 ]
  • (Z)-4-(5-hydroxy-1-(3-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-en-1-yl)phenol dihydrochloride salt [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 64
  • [ 540752-87-2 ]
  • (E)-3-(5-hydroxy-1-(3-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-en-1-yl)phenol dihydrochloride salt [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 65
  • [ 540752-87-2 ]
  • [ 591-50-4 ]
  • C17H20O4 [ No CAS ]
  • (E)-tert-butyl 4-(3-(5-methoxy-5-oxo-2-phenyl-1-(3-(pivaloyloxy)phenyl)pent-1-en-1-yl)phenyl)piperazine-1-carboxylate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 1837 - 1858
  • 66
  • [ 540752-87-2 ]
  • [ 1346818-11-8 ]
  • C28H32ClFN4O3 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With palladium bis[bis(diphenylphosphino)ferrocene] dichloride; caesium carbonate; In water; toluene; at 80℃; for 12h;Inert atmosphere; General procedure: 5-bromo-3-(1-(2-chloro-5-fluorophenyl)ethoxy)pyridin-2-amine(3.735 g, 10.8 mmol), cesium carbonate (12.382 g, 38.0 mmol) and tert-butyl4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylatewas(4.915g,13.0 mmol) was dissolved in Toluene (15 mL) and water (2 mL). The reactionsolution was purged with N2 for 20 minutes, then PdCl2(dppf)2(0.794mg, 1.1 mmol) was added and the mixture was purged with N2 for 10minutes. The resulting mixture was stirred for 12 h at 80 oC under N2.After cooling down the mixture toroom temperature, the solution wasconcentrated with a rotary evaporator. The crude productwas purified by silica gel chromatography (dichloromethane/methanol = 100: 1,v/v) to obtain the product as a yellow oil (4.761 g, 85 %).
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 1507 - 1513
  • 67
  • [ 540752-87-2 ]
  • 5,5-difluoro-7,9-dimethyl-3-(3-oxo-3-((3-((4-(3-(piperazin-1-yl)phenyl)pyrimidin-2-yl)amino)phenyl)amino)propyl)-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide [ No CAS ]
Reference： [1]Patent: US2020/95240,2020,A1
  • 68
  • [ 540752-87-2 ]
  • 3-(3-((3-((4-(3-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenyl)pyrimidin-2-yl)amino)phenyl)amino)-3-oxopropyl)-5,5-difluoro-7,9-dimethyl-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide [ No CAS ]
Reference： [1]Patent: US2020/95240,2020,A1

Tags: 540752-87-2 synthesis path| 540752-87-2 SDS| 540752-87-2 COA| 540752-87-2 purity| 540752-87-2 application| 540752-87-2 NMR| 540752-87-2 COA| 540752-87-2 structure

Same Skeleton Products
Related Products
Historical Records

Related Functional Groups of
[ 540752-87-2 ]

Organoboron

Chemical Structure| 470478-90-1

[ 470478-90-1 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate

Similarity: 0.99

Chemical Structure| 1190423-36-9

[ 1190423-36-9 ]

tert-Butyl (tert-butoxycarbonyl)(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)carbamate

Similarity: 0.91

Chemical Structure| 330793-01-6

[ 330793-01-6 ]

tert-Butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

Similarity: 0.91

Chemical Structure| 893441-86-6

[ 893441-86-6 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

Similarity: 0.83

Chemical Structure| 1161362-35-1

[ 1161362-35-1 ]

tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate

Similarity: 0.81

Aryls

Chemical Structure| 470478-90-1

[ 470478-90-1 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate

Similarity: 0.99

Chemical Structure| 330793-01-6

[ 330793-01-6 ]

tert-Butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

Similarity: 0.91

Chemical Structure| 1912446-60-6

[ 1912446-60-6 ]

tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate

Similarity: 0.85

Chemical Structure| 262444-42-8

[ 262444-42-8 ]

tert-Butyl 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate

Similarity: 0.79

Chemical Structure| 330794-35-9

[ 330794-35-9 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate

Similarity: 0.78

Amides

Chemical Structure| 470478-90-1

[ 470478-90-1 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate

Similarity: 0.99

Chemical Structure| 1190423-36-9

[ 1190423-36-9 ]

tert-Butyl (tert-butoxycarbonyl)(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)carbamate

Similarity: 0.91

Chemical Structure| 330793-01-6

[ 330793-01-6 ]

tert-Butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

Similarity: 0.91

Chemical Structure| 893441-86-6

[ 893441-86-6 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

Similarity: 0.83

Chemical Structure| 1161362-35-1

[ 1161362-35-1 ]

tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate

Similarity: 0.81

Related Parent Nucleus of
[ 540752-87-2 ]

Piperazines

Chemical Structure| 470478-90-1

[ 470478-90-1 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate

Similarity: 0.99

Chemical Structure| 1310404-00-2

[ 1310404-00-2 ]

tert-Butyl 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperazine-1-carboxylate

Similarity: 0.77

Chemical Structure| 656257-45-3

[ 656257-45-3 ]

4-(4-Ethylpiperazin-1-yl)phenylboronic acid pinacol ester

Similarity: 0.77

Chemical Structure| 496786-98-2

[ 496786-98-2 ]

tert-Butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate

Similarity: 0.71

Chemical Structure| 1150114-76-3

[ 1150114-76-3 ]

(4-(4-(tert-Butoxycarbonyl)piperazine-1-carbonyl)phenyl)boronic acid

Similarity: 0.65